157 related articles for article (PubMed ID: 36803751)
1. Combination Therapy with Androgen Receptor Pathway Inhibitors for Prostate Cancer.
Blas L; Shiota M
Curr Cancer Drug Targets; 2023; 23(6):428-432. PubMed ID: 36803751
[No Abstract] [Full Text] [Related]
2. Androgen receptors in early and castration resistant prostate cancer: friend or foe?
Pelekanou V; Notas G; Stathopoulos EN; Castanas E; Kampa M
Hormones (Athens); 2013; 12(2):224-35. PubMed ID: 23933691
[No Abstract] [Full Text] [Related]
3. Evolution of androgen receptor targeted therapy for advanced prostate cancer.
Wong YN; Ferraldeschi R; Attard G; de Bono J
Nat Rev Clin Oncol; 2014 Jun; 11(6):365-76. PubMed ID: 24840076
[TBL] [Abstract][Full Text] [Related]
4. Targeting the androgen receptor in metastatic castration-resistant prostate cancer.
Aragon-Ching JB
Future Oncol; 2014 Feb; 10(3):329-32. PubMed ID: 24559439
[No Abstract] [Full Text] [Related]
5. The biology of castration-resistant prostate cancer.
Lian F; Sharma NV; Moran JD; Moreno CS
Curr Probl Cancer; 2015; 39(1):17-28. PubMed ID: 25547388
[No Abstract] [Full Text] [Related]
6. Clinical observations regarding the use of androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Oh WK
Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):13-16. PubMed ID: 35579580
[No Abstract] [Full Text] [Related]
7. Factors that guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer: Q&A.
Oh WK; Rettig MB
Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):16-17. PubMed ID: 35579581
[No Abstract] [Full Text] [Related]
8. How patient characteristics can guide selection among androgen receptor inhibitors in patients with nonmetastatic castration-resistant prostate cancer.
Rettig MB
Clin Adv Hematol Oncol; 2022 May; 20 Suppl 9(5):9-12. PubMed ID: 35579579
[No Abstract] [Full Text] [Related]
9. How quality of life can help guide selection of androgen receptor inhibitors in nonmetastatic castration-resistant prostate cancer.
Smith MR
Clin Adv Hematol Oncol; 2021 Oct; 19(10):627-630. PubMed ID: 34637427
[No Abstract] [Full Text] [Related]
10. Galeterone activity in castration-resistant prostate cancer.
Yaqub F
Lancet Oncol; 2015 Jan; 16(1):e10. PubMed ID: 25638544
[No Abstract] [Full Text] [Related]
11. Targeting Androgen Receptor Aberrations in Castration-Resistant Prostate Cancer.
Sharp A; Welti J; Blagg J; de Bono JS
Clin Cancer Res; 2016 Sep; 22(17):4280-2. PubMed ID: 27330057
[TBL] [Abstract][Full Text] [Related]
12. [New generation of androgen receptor antagonist in castration resistant prostate cancer].
Uemura H
Nihon Rinsho; 2014 Dec; 72(12):2164-9. PubMed ID: 25518352
[TBL] [Abstract][Full Text] [Related]
13. [ASC-J9 for castration-resistant prostate cancer].
Yamashita S; Arai Y
Nihon Rinsho; 2014 Dec; 72(12):2126-9. PubMed ID: 25518345
[TBL] [Abstract][Full Text] [Related]
14. The role of intracrine androgen metabolism, androgen receptor and apoptosis in the survival and recurrence of prostate cancer during androgen deprivation therapy.
Fiandalo MV; Wu W; Mohler JL
Curr Drug Targets; 2013 Apr; 14(4):420-40. PubMed ID: 23565755
[TBL] [Abstract][Full Text] [Related]
15. Cases in the management of nonmetastatic castration-resistant prostate cancer: darolutamide as the first androgen receptor inhibitor in a fit, older man.
Lowentritt BH
Clin Adv Hematol Oncol; 2022 Jan; 20 Suppl 1(1):1-8. PubMed ID: 35343943
[No Abstract] [Full Text] [Related]
16. Androgen receptor signalling impairs docetaxel efficacy in castration-resistant prostate cancer.
Mout L; Moll JM; Chen M; de Morrée ES; de Ridder CMA; Gibson A; Stuurman D; Aghai A; Erkens-Schulze S; Mathijssen RHJ; Sparreboom A; de Wit R; Lolkema MP; van Weerden WM
Br J Cancer; 2020 Dec; 123(12):1715-1719. PubMed ID: 32989230
[TBL] [Abstract][Full Text] [Related]
17. Abiraterone acetate, a first-in-class CYP17 inhibitor, establishes a new treatment paradigm in castration-resistant prostate cancer.
Bedoya DJ; Mitsiades N
Expert Rev Anticancer Ther; 2012 Jan; 12(1):1-3. PubMed ID: 22149426
[No Abstract] [Full Text] [Related]
18. Degradation of Androgen Receptor through Small Molecules for Prostate Cancer.
Ge R; Xu X; Xu P; Li L; Li Z; Bian J
Curr Cancer Drug Targets; 2018; 18(7):652-667. PubMed ID: 29110617
[TBL] [Abstract][Full Text] [Related]
19. [Not Available].
Bernemann C; Bögemann M; Steinestel J; Schrader AJ
Oncol Res Treat; 2017; 40 Suppl 2():8-10. PubMed ID: 28365708
[TBL] [Abstract][Full Text] [Related]
20. Hormonal Therapy for Prostate Cancer.
Desai K; McManus JM; Sharifi N
Endocr Rev; 2021 May; 42(3):354-373. PubMed ID: 33480983
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
